Abstract Library

#4564 Vasculogenic mimicry in neuroendocrine tumour across different primary sites

Introduction: Anti-angiogenesis treatments targeting VEGFRs, including Surufatinib and Cabozantinib, etc. showed better efficacy for pancreatic neuroendocrine tumours (NET) than NET of other primary sites. Recent clinical trial targeting tumour necrosis factor receptor-associated protein-1, leading to inhibition of vasculogenic mimicry (VM) showed contrary results to current VEGFRs-targeted treatments. However, VM of NET across different primary sites are yet to be understood.

Conference:

Presenting Author: Chen L

Authors: Chen L, Liang Y, Huang D, Ji S, Chen J,

Keywords: neuroendocrine tumour, pancreatic, extra-pancreatic, vasculogenic mimicry,

#4399 Updated data from a single-arm, open-label, multicentre clinical study on the efficacy and safety of surufatinib combined with EP regimen and serplulimab in first-line treatment of NEC

Introduction: NEC is an aggressive neuroendocrine neoplasm with limited treatment options. Surufatinib (SUR), a kinase inhibitor targeting VEGFRs, FGFR-1, and CSF-1R, improves vascular normalisation and tumour microenvironment, synergising with chemo- and immunotherapy.

Conference:

Presenting Author: Lin Z

Authors: Zhang T, Lin Z, Zhao L, Ma H, Zhang D,

Keywords: NEC, surufatinib, EP, first-line,

#4035 The safety and efficacy of surufatinib for the treatment of advanced neuroendocrine tumors: A prospective, multicenter, real-world study

Introduction: Surufatinib (a small-molecule inhibitor of VEGFR1-3, FGFR1, and CSF-1R) has exhibited encouraging antitumor activity for the treatment of advanced neuroendocrine tumors (including NET and NEC) in multiple registration studies.

Conference:

Presenting Author: Jiang L

Authors: Jiang L, Chuntao W, Beiyuan H, Tao C, Haitao G,

Keywords: neuroendocrine tumor, real-world study, surufatinib,

#3949 Real-world study of Surufatinib combined with hepatic artery infusion chemotherapy (HAIC) for high-grade neuroendocrine neoplasm

Introduction: Current therapeutic schedules of liver metastasis-dominated extrapulmonary high-grade neuroendocrine neoplasm (HG-NEN) have limited clinical benefits and liver metastasis progression is the main cause of death. Surufatinib (SUR, a selective VEGFRs, FGFR1 and CSF-1R inhibitor) showed promising antitumor activity in neuroendocrine neoplasm.

Conference:

Presenting Author:

Authors: Wang Y, Yu H, Yang D, Liu H, Yao W,

Keywords: Real-world study, surufatinib, hepatic artery infusion chemotherapy, high-grade neuroendocrine neoplasm,

#3933 Surufatinib plus Sintilimab and IBI310 in patients with high-grade advanced-neuroendocrine neoplasm (HG-NEN): A multicenter, single arm phase 2 study

Introduction: Surufatinib (SUR, a selective VEGFRs, FGFR1 and CSF-1R inhibitor). Preclinical and clinical studies have shown that SUR is the best partner of immune checkpoint inhibitors (ICI).

Conference:

Presenting Author: Zhang P

Authors: Zhang P, Wang Y, Li J, Shen L, Lu M,

Keywords: Surufatinib, Sintilimab, IBI310, high-grade advanced-neuroendocrine neoplasm,